Is the response of serum lipids and lipoproteins to postmenopausal hormone replacement therapy modified by apoE genotype?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 2, 1999, Pages 402-407

  Heikkinen, Anna Mari ^a   Niskanen, Leo ^a   Ryynänen, Markku ^a   Komulainen, Marja H ^a   Tuppurainen, Marjo T ^a   Parviainen, Markku ^a   Saarikoski, Seppo ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

ApoE genotype; LDL cholesterol; Postmenopausal hormone replacement therapy; Prospective study

Indexed keywords

APOLIPOPROTEIN E; CYPROTERONE ACETATE; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033007960     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.2.402     Document Type: Article

References (32)

1. Mahley RW. Apoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-640.
2. Ehnholm C, Lukka M, Kuusi T, Nikkilä E, Uterman G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res. 1986;27:227-235.
3. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res. 1992;240:447-454.
4. Davignon J, Gregg RE, Sing SF. Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis. 1988;8:1-21.
5. Tiret L, Knijff P, Menzel H-J, Ehnholm C, Nicaud V, Havekes LM. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations: the EARS study: European Atherosclerosis Research Study. Arterioscler Thromb. 1994;14:1617-1624.
6. Eggertsen G, Tegelman R, Ericsson S, Angelin B, Berglund L. Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations. Clin Chem. 1993;39:2125-2129.
7. Kamboh MI, Aston CE, Ferrell RE, Hamman RF. Impact of apolipoprotein E polymorphism in determining interindividual variation in total cholesterol and low density lipoprotein cholesterol in Hispanics and non-Hispanic whites. Atherosclerosis. 1993;98:201-211.
8. Ferrières J, Sing CF, Roy M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: sex-specific effects. Arterioscler Thromb. 1994;14:1554-1560.
9. Schaefer EJ, Lamon-Fava S, Johnson S, Ordovas JM, Schaefer MM, Castelli WP, Wilson PWF. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels: results from the Framingham Offspring Study. Arterioscler Thromb. 1994;14:1105-1113.
10. Miettinen TA, Gylling H, Vanhanen H, Ollus A. Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apoprotein E phenotypes. Arterioscler Thromb. 1992;12:1044-1052.
11. Lopez-Miranda J, Ordovas JM, Mata P, Lichtenstein AH, Clevidence B, Judd JT, Schaefer JE. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. J Lipid Res. 1994;35:1965-1975.
12. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park J-S, Cole T, Schaefer EJ. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis. 1995;13:157-166.
13. Barret-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
14. Tuppurainen M, Honkanen R, Kröger H, Saarikoski S, Alhava E. Osteoporosis risk factors, gynecological history and fractures in perimenopausal women - the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention Study. Maturitas. 1993;17: 89-100.
15. Heikkinen A-M, Tuppurainen M, Niskanen L, Komulainen M, Penttilä I, Saarikoski S. Long-term vitamin D3 supplementation may have adverse effects on postmenopausal hormone replacement therapy. Eur J Endocrinol. 1997;137:495-502.
16. Heinonen M, Lampi A-M, Hyvönen L, Homer D. The fatty acid and cholesterol content of the average Finnish diet. J Food Comp Anal. 1992;5:198-208.
17. Penttilä IM, Voutilainen E, Laitinen P, Juutilainen P. Comparison of different analytical and precipitation methods for direct estimation of serum high-density lipoprotein cholesterol. Scand J Clin Lab Invest. 1981;41:353-360.
18. Friedewald WT, Levy RI, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparation ultracentrifuge. Clin Chem. 1972;18:499-502.
19. Knowlton RG, Weaver EJ, Struyk AF, Knobloch WH, King RA, Norris K, Shamban A, Uitto J, Jimenez SA, Prockop DJ. Genetic linkage analysis of hereditary arthro-ophthalmopathy (Stickler syndrome) and the type II procollagen gene. Am J Hum Genet. 1989;45:681-688.
20. Hixon JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31: 545-548.
21. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csazar A, Utermann G. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet. 1991;49:338-349.
22. Walsh BW, Sciff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
23. The Writing Group for the PEPI Trial. Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1995;273:199-208.
24. Rijpkema AMH, Van der Sanden AA, Ruijs AHC. Effects of postmenopausal oestrogen progestogen replacement therapy serum lipids and lipoproteins: a review. Maturitas. 1990;12:259-285.
25. Tikkanen MJ, Kuusi T, Vartiainen E, Nikkilä EA. Treatment of postmenopausal hypercholesterolemia with oestradiol. Acta Obstet Gynecol. 1979;84:222-226.
26. Farish E, Fletcher CD, Dagen MM, Hart DM, Al-Azzawi F, Parkin DE, Howie CA. Lipoprotein and apolipoprotein levels in postmenopausal women on continuous oestrogen/progestogen therapy. Br J Obstet Gynecol. 1989;96:358-364.
27. Mänttäri M, Koskinen P, Enholm C, Huttunen JK, Manninen V. Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention. Metabolism. 1991;40:217-221.
28. Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, Ershow A, Pearson TA, Roheim PS, Ramakrishnan R, Derr J, Gordon DJ, Reed R, for the DELTA Reasearch Group. ApoE genotype does not predict lipid response to changes in dietary saturated fatty acids in a heterogeneous normolipidemic population. Arterioscler Thromb Vasc Biol. 1997;17:2914-2923.
29. Pasagian-Macaulay A, Aston CE, Ferell RE, McAllister AE, Wing RR, Kuller LH. A dietary and behavioral intervention design to lower coronary heart disease: risk factors are unaffected by variation at the APOE gene locus. Atherosclerosis. 1997;132:221-227.
30. Jensen J, Nilas L, Christiansen C. Influence on menopause on serum lipids and lipoproteins. Maturitas. 1990;12:321-331.
31. Pietinen P, Vartiainen E, Seppäinen R, Aro A, Puska P. Changes in diet in Finland from 1972 to 1992: impact on coronary heart disease risk. Prev Med. 1996;25:243-250.
32. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism. 1993;42:895-901.